IVD
In Vitro Diagnostics
In Vitro Diagnostics (IVD) play an important role in modern healthcare by providing insights into patients’ health through the analysis of samples outside the body, such as blood or urine. These tests enable early disease detection, aid in treatment decisions, and facilitate personalized medicine with the goal of improving patient outcomes and reducing healthcare costs. This value, however, heavily depends on the context in which a test is used, highlighting the importance of dynamic health economic analyses.
Our solutions are specifically developed for the application type of your product. We offer applications for diagnostic products such as blood tests and medical imaging, prognostic products including predictive algorithms, companion diagnostics, and therapeutics.
Diagnostics encompasses a range of technologies and tools designed to detect and monitor diseases.
Prognostics involves the use of technologies and algorithms to predict the likely course and outcome of diseases.
Companion diagnostics are specialized tests that identify patients most likely to benefit from specific treatments, enabling personalized therapies.
Treatment sequencing strategically orders therapies to maximize efficacy, reduce side effects, and improve patient outcomes.
Join the discussion
Discuss your evidence approach with us
Get a practical walkthrough of how the platform can support clearer, locally relevant assessment of diagnostic AI, medtech, biotech, and pharma products.
Products
Designed to help you maximize the value of your diagnostic, prognostic, or companion diagnostic product.
Medip Analytics offers a cost-effectiveness evaluation service for your diagnostic, prognostic, or companion diagnostic product across any disease area.
Database and analysis of cost data from US hospitals. Search for healthcare costs based on CPT-code.
Our consultancy services are designed to assist companies with all health economic questions. We leverage our scientific expertise and extensive experience to advise you on your health economic strategy.
